.png)
EuPOP Life Sciences Accelerates Global Business Development for Premium Vaccines at BIO USA 2026
June 2, 2026
EuPOP Life Sciences (EuPOP) is actively pursuing global licensing agreements and strategic co-development partnerships at the BIO International Convention 2026 (BIO USA) held in San Diego, USA. For this premier global event, EuPOP is participating alongside its newly contracted US-based specialized consulting firms and its Chief Technology Officer (CTO), Dr. Jonathan Lovell, to engage in comprehensive one-on-one partnering meetings with global pharmaceutical giants and institutional investors.
At the center of these global discussions are EuPOP's next-generation premium vaccine programs, including candidates for Respiratory Syncytial Virus (RSV), shingles (HZV), and Alzheimer's disease (AD). The clinical timelines for these key assets have become highly visible; final Clinical Study Reports (CSR) for the RSV and shingles Phase 1 trials are scheduled to be secured sequentially in July and September 2026. Furthermore, the company is on track to submit an Investigational New Drug (IND) application for its innovative Alzheimer's therapeutic vaccine within the third quarter of this year.
Backed by the robust, cash-generating public vaccine business of its major partner EuBiologics, EuPOP ensures long-term financial stability to advance these high-value projects. The company aims to leverage its proprietary antigen display technology and rigorous clinical progression to secure global market shares and establish itself as a premier innovator in the global biopharmaceutical industry.
To learn more, please click here: